We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eli Lilly and Co | NYSE:LLY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 781.10 | 1,750 | 12:45:01 |
From Nov 2023 to May 2024
By Denny Jacob
Eli Lilly's Jaypirca was approved by the Food and Drug Administration to treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy.
The Indianapolis-based pharmaceutical company said Friday that Jaypirca was approved under the FDA's accelerated approval pathway based on results from a trial.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 01, 2023 17:51 ET (22:51 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Eli Lilly Chart |
1 Month Eli Lilly Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
